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Chemoprevention is a risk reduction option for women who have increased risk of breast cancer. 
Selective Estrogen Receptor Modulators (SERMs) have been extensively tested, and alternative agents 
are being evaluated. Long-term adherence to chemoprevention is critical to obtaining the drug’s full 
benefit. We systematically reviewed articles reporting uptake rates and adherence among healthy adult 
women, who were prescribed medication to prevent primary breast cancer. We also extracted data on the 
clinical, socio-demographic and psychological predictors of uptake and adherence.  
Searches were performed in PubMed, CINAHL, EMBASE, and PsychInfo, yielding 3851 unique articles. 
Title, abstract and full text screening left 53 articles that met inclusion criteria, and a further 4 studies 
were identified from reference lists, giving a total of 57. The mean quality score using the Mixed Methods 
Appraisal Tool was 3 out of 4. 
Thirty-one articles reported uptake, of which 14 tested predictors, and 23 reported adherence of which 11 
tested predictors.  Seven studies reported qualitative data. Most studies (50) involved SERMs, but 5 tested 
Aromatase Inhibitors, 1 tested Aspirin, 1 tested a statin. Twenty studies included data from a clinical 
setting, 35 reported trial data, and 2 reported both.  
Twenty-four studies reporting 26 instances of uptake in 21,423 women were included in a meta-analysis. 
The pooled uptake estimate was 16.3% (95% CI, 13.6-19.0), with high heterogeneity (I^2=98.9%, 
p<0.0001). Uptake was unaffected by study location or agent, but was significantly higher in trials (25.2% 
[95% CI, 18.3-32.2]) than in clinical settings (8.7% [95% CI, 6.8-10.9]). Factors associated with higher 
uptake in two or more studies included having an abnormal biopsy, a physician recommendation, higher 
objective risk, fewer side-effect or trial-related concerns, and older age.  Heterogeneity in data collection 
prevented a meta-analysis of adherence. Data suggested adequate day-to-day adherence among women 
who initiated treatment, with 5/6 studies reporting ≥80% of medications being taken appropriately. 
Persistence over 3-12 months was also high, with 5/7 studies reporting that ≥80% women were still taking 
chemoprevention. Long-term persistence was lower, with only 1/10 studies reporting a persistence of 
≥80% by 5-years.  Factors associated with lower adherence or persistence included allocation to 
Tamoxifen (vs. placebo or Raloxifene), depression, smoking, and older age. Objective and subjective risk 
was a theme in all qualitative studies, although other topics involved in decision-making included 
concerns about medications (6/7), low knowledge (3/7), lack of information (2/7), and trial-related issues 
(2/7).  
Chemoprevention uptake for the prevention of breast cancer is low, and long-term adherence is often 
insufficient for the full preventive effect. Uptake rates were higher in trials than in clinical settings, 
suggesting further work should focus on implementing chemoprevention within routine patient care. 
Further research is warranted to identify factors amenable to modification and to improve informed 
decision-making surrounding chemoprevention.  
